The effects of NN414, a SUR1/Kir6.2 selective potassium channel opener in subjects with type 2 diabetes.

M Zdravkovic, M Kruse, K L Rost, J Møss, A Kecskes

Journal: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2007;115(6):405-6

PMID: 17701889

Full Text on Georg Thieme Verlag Stuttgart, New York View on PubMed

Abstract

Reducing the workload of the beta cell by inhibiting insulin secretion may provide beneficial effects for patients with type 2 diabetes. The aim of this study was to investigate the effect of NN414, a beta cell selective potassium channel opener in patients with type 2 diabetes. 24 patients were treated for seven days (placebo, 1.5, 4.5, and 10 mg/kg). In accordance with the pharmacological profile a significant and selective inhibition of insulin secretion was observed (1 h post dose). There were no statistically significant effects on overall glycaemic control. Based on OGTT derived parameters a borderline significant improvement in beta-cell function (1st and 2nd phase insulin secretion) was observed from Day 1 to Day 7.

Address: Novo Nordisk A/S, Global Development, Denmark. [email protected]

DOI: 10.1055/s-2007-973062

Link outs

Free resources

Medical:

https://medlineplus.gov/diabetestype2.html

Subscription / membership required

Full Text Sources:

https://www.thieme-connect.com/DOI/DOI?10.1055/s-2...

MeSH Terms: ATP-Binding Cassette Transporters, Aged, Bridged Bicyclo Compounds, Heterocyclic, Cyclic S-Oxides, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Insulin, Insulin Secretion, Insulin-Secreting Cells, Male, Middle Aged, Potassium Channels, Potassium Channels, Inwardly Rectifying, Receptors, Drug, Sulfonylurea Receptors, Time Factors